Published in N Engl J Med on January 17, 2013
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest (2014) 1.52
Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol (2014) 1.14
Drug-eluting coronary-artery stents. N Engl J Med (2013) 0.99
Drug-eluting coronary-artery stents. N Engl J Med (2013) 0.99
Dual modality intravascular optical coherence tomography (OCT) and near-infrared fluorescence (NIRF) imaging: a fully automated algorithm for the distance-calibration of NIRF signal intensity for quantitative molecular imaging. Int J Cardiovasc Imaging (2014) 0.95
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci (2015) 0.93
MicroRNAs and Endothelial (Dys) Function. J Cell Physiol (2015) 0.93
microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. Adv Exp Med Biol (2015) 0.89
Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study. Biomed Rep (2015) 0.87
Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study. Heart Vessels (2014) 0.87
Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells. Differentiation (2015) 0.84
Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis. J Am Heart Assoc (2014) 0.82
External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clin Res Cardiol (2016) 0.81
Preoperative management of antiplatelet drugs for a coronary artery stent: how can we hit a moving target? BMC Anesthesiol (2014) 0.81
A cross-sectional study of stand-alone percutaneous coronary intervention in a Nigerian cardiac catheterization laboratory. BMC Cardiovasc Disord (2014) 0.81
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol (2014) 0.81
Drug-eluting coronary-artery stents. N Engl J Med (2013) 0.80
Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol (2014) 0.80
Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention. Am Heart J (2014) 0.80
Transradial versus transfemoral rotablation for heavily calcified coronary lesions in contemporary drug-eluting stent era. J Geriatr Cardiol (2015) 0.78
Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis (2013) 0.77
Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
Bioengineered Corneas Grafted as Alternatives to Human Donor Corneas in Three High-Risk Patients. Clin Transl Sci (2015) 0.77
Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction. Arq Bras Cardiol (2014) 0.76
Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. J Thorac Dis (2016) 0.75
Rotational atherectomy: an Update. J Geriatr Cardiol (2013) 0.75
Spectral analysis related to bare-metal and drug-eluting coronary stent implantation. Arq Bras Cardiol (2014) 0.75
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. J Am Heart Assoc (2016) 0.75
Application of quality by design (QbD) approach to ultrasonic atomization spray coating of drug-eluting stents. AAPS PharmSciTech (2015) 0.75
Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: A PRISMA-compliant meta-analysis of randomized clinical trials. Medicine (Baltimore) (2017) 0.75
Effects of Low Endothelial Shear Stress After Stent Implantation on Subsequent Neointimal Hyperplasia and Clinical Outcomes in Humans. J Am Heart Assoc (2016) 0.75
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents. PLoS One (2014) 0.75
Drug deposition in coronary arteries with overlapping drug-eluting stents. J Control Release (2016) 0.75
Invasive management of acute coronary syndromes. Lancet (2016) 0.75
Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis (2016) 0.75
Telomerase Inhibition by Everolimus Suppresses Smooth Muscle Cell Proliferation and Neointima Formation Through Epigenetic Gene Silencing. JACC Basic Transl Sci (2016) 0.75
Coronary stenting: A matter of revascularization. World J Cardiol (2017) 0.75
Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag (2015) 0.75
Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond) (2016) 0.75
Inhibition of early AAA formation by aortic intraluminal pentagalloyl glucose (PGG) infusion in a novel porcine AAA model. Ann Med Surg (Lond) (2016) 0.75
Bio-Adaption between Magnesium Alloy Stent and the Blood Vessel: A Review. J Mater Sci Technol (2015) 0.75
Healing the injured vessel wall using microRNA-facilitated gene delivery. J Clin Invest (2014) 0.75
Enhancing physiologic simulations using supervised learning on coarse mesh solutions. J R Soc Interface (2015) 0.75
Biomedical therapy using synthetic WKYMVm hexapeptide. Organogenesis (2016) 0.75
Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord (2017) 0.75
Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes. Arq Bras Cardiol (2015) 0.75
Optimal choice of coronary revascularization and stent type in diabetic patients with coronary artery disease. Cardiol Ther (2013) 0.75
Percutaneous coronary intervention patients' and cardiologists' experiences of the informed consent process in Northern England: a qualitative study. BMJ Open (2017) 0.75
Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep (2017) 0.75
Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol (2017) 0.75
Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study. Int J Cardiovasc Imaging (2016) 0.75
Extracting information from free-text electronic patient records to identify practice-based evidence of the performance of coronary stents. PLoS One (2017) 0.75
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2007) 2.88
Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation (2003) 2.81
Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv (2011) 2.63
Myocardial bridging. Eur Heart J (2005) 2.56
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol (2003) 2.52
Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol (2005) 2.51
Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv (2010) 2.51
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol (2012) 2.44
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA (2004) 2.32
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation (2006) 2.29
Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv (2009) 2.24
Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol (2005) 2.21
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation (2005) 2.03
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation (2002) 2.00
Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv (2002) 1.98
The history of the German Cardiac Society and the American College of Cardiology and their two founders. J Am Coll Cardiol (2013) 1.97
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (2007) 1.91
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation (2002) 1.88
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation (2004) 1.87
Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation (2012) 1.87
Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol (2009) 1.87
A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol (2006) 1.84
Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv (2011) 1.80
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation (2008) 1.77
Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg (2011) 1.77
Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J (2013) 1.76
Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc (2002) 1.74
Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol (2003) 1.74
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 1.73
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol (2007) 1.68
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension (2008) 1.67
Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv (2011) 1.66
The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J (2006) 1.65
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J (2006) 1.63
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.62
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J (2004) 1.60
Long-term mortality of coronary artery bypass grafting and bare-metal stenting. Ann Thorac Surg (2011) 1.60
30-day readmission for patients undergoing percutaneous coronary interventions in New York state. JACC Cardiovasc Interv (2011) 1.59
Enhanced external counterpulsation for ischemic heart disease: what's behind the curtain? J Am Coll Cardiol (2003) 1.59
Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation (2002) 1.57
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
The truth and consequences of the COURAGE trial. J Am Coll Cardiol (2007) 1.55
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation (2004) 1.54
Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J (2008) 1.53
Medical device innovation: prospective solutions for an ecosystem in crisis. Adding a professional society perspective. JACC Cardiovasc Interv (2012) 1.53
Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation (2012) 1.52
Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA (2011) 1.51
Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv (2012) 1.51
Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2004) 1.51
Staged versus one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction. Circ Cardiovasc Interv (2013) 1.51
Turf wars and silos-joined at the hip: what can be done? Catheter Cardiovasc Interv (2007) 1.50
Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up. Am Heart J (2003) 1.50
Location of femoral artery access and correlation with vascular complications. Catheter Cardiovasc Interv (2011) 1.50
Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med (2004) 1.50
Transcatheter valve therapy: a professional society overview from the American College of Cardiology Foundation and the Society of Thoracic Surgeons. Ann Thorac Surg (2011) 1.49
Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2008) 1.49
Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA (2011) 1.48
Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv (2004) 1.48
Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. Ann Thorac Surg (2016) 1.48
Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J (2004) 1.47
Immediate ambulation following diagnostic coronary angiography procedures utilizing a vascular closure device (The Closer). J Invasive Cardiol (2002) 1.47
Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv (2010) 1.47
Statistical SPECT processing in MRI-negative epilepsy surgery. Neurology (2014) 1.46
Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv (2008) 1.45